Advances in science: next generation of lab tools, models and testing platforms used in predictive toxicology

THE RISE OF PREDICTIVE TOXICOLOGY METHODOLOGIES
Toxicology testing platforms are an integral part of the human health risk assessment process that determines whether an ingredient or fi nal formulation may induce harm to humans commensurate with accidental or intentional exposure. Th e process uses quantitative and qualitative methodologies that address hazard identifi cation, dose-response assessment, exposure assessment, and risk characterization. It is the paramount responsibility of manufacturers within their respective industry sector (pharmaceutical, personal care, etc.) to ensure the safety of their products within a framework with various levels of regulatory requirements.
Historically, safety assessment has been performed using animal-based test methods (in vivo) that provide whole organism responses to toxicants. Th e toxicologist relied upon the animal tests to closely predict human response to hazards despite the imperfections introduced by inter-species extrapolations that are used to address the natural diff erences in anatomy and physiology. Due to the large number of products put on the market continuously, the requirement to protect public welfare by extensive evaluation of potential hazardous eff ects they may induce upon human exposure becomes a very challenging task. Th erefore, novel and more effi cient safety assessment methodologies need to be designed, evaluated and added to the predictive toxicology toolbox. We enter nowadays a modern scientifi c era that introduces Predictive Toxicology testing strategies encompassing a wide array of cutting edge methodologies that aim to reliably predict the human response to toxicants rather than observe the eff ects in animal-based test systems as in the classic toxicology approaches.
Th e lab tools, models and testing platforms currently integrated in the fi eld of predictive toxicology can highlight areas where candidate molecules or prototypes may pose as hazardous at very early stages. Th us, they facilitate a quick and reliable selection process before further pre-clinical development and ultimately clinical trials are performed if and where applicable. Predictive toxicology refl ects a paradigm shift from in vivo testing methods and initially promoted a wide array of alternative methods ranging from simple monoculture test systems to more complex explants or reconstructed tissue models. Th ese available in vitro systems became instrumental for the investigation of cellular and molecular mechanisms underlying biological eff ects induced by exposure to toxicants. Furthermore, the combination between modern in silico approaches designed based on experimental data generated by in vivo and in vitro assays and cutting edge data mining algorithms contributes to the development of powerful predictive models (1) . In recent years, the complexity of the testing platforms increased by the introduction of sophisticated bio-printed tissues and microphysiological systems (organs-on-a-chip/plate). Th ey announce a yet another global paradigm shift in toxicology by enabling collection of valuable insights into acute systemic response that was not possible before. Based on its available technology platforms, the fi eld of predictive toxicology supports ongoing 3Rs initiatives and eff orts to Replace, Refi ne and Reduce animal usage for safety assessment of chemicals, drugs, etc.
Th e principles predictive toxicology is based upon and the various levels of complexity its methodologies can off er in multiple combinations towards the goal of ensuring human safety steadily gained popularity amongst multiple players with vested and overlapping interests in advancing the fi eld further. Industry (manufacturers, biotech companies, contract research organizations, trade associations), academia, regulatory agencies, animal welfare groups and the public are all drivers of advanced, modern predictive toxicology methodologies. By off ering the potential for reliable, reproducible, fast and more cost eff ective results, these new approaches can be employed in a sequential or tiered manner and have a signifi cant impact on the product development process and on the regulatory testing framework.
THE REDUCTIONIST CONCEPT AND EMERGING TECHNOLOGIES
Toxicity testing in the 21 st century refl ects the process of transition from the traditional toxicant-related observations in whole animal models to mechanism-based outcomes from cell/tissue/chips-based assays and compu tational methods. As already demonstrated in the regulatory framework, it is however unrealistic to believe that a single assay or model will provide suffi cient information on the risk or hazard posed by a chemical despite their multitude, diversity and relatively high prediction accuracy. Th erefore, data need to be generated by a variety of well controlled protocols, thoroughly analyzed and integrated in a framework capable to maximize their utility for accurate predictions.
Th e reductionist concept of in vitro models and the recent orientation towards methods derived from or based on human biological components best refl ects the evolution of the fi eld and is explained in Fig. 1 using the ocular safety assessment as one key endpoint in the evaluation of raw ingredients and formulations. Th e safety of products was primarily performed starting in the '40s using the Draize test conducted in albino rabbits as the only available method at the time (2) . Science advanced the technology towards the use of the isolated eyeball as the target organ presumed to provide similar results when exposed to toxicants without the need to use whole animal test systems. Isolated eyes (rabbit, chicken) ( Fig. 1 ) usually obtained by testing laboratories as byproducts from abattoirs are used to assess the safety of products based on assays validated for regulatory purposes (3, 4) . Following the reductionist concept, the narrowing of the test system to the primary target of a toxicant when coming in contact with the eye (the cornea) continued when pharmaceutical industry (Merck) (5) designed a now validated in vitro assay (6) based on excised corneas from bovine eyes obtained as byproduct from meat production. While initially designed to address severe irritants, the Bovine Corneal Opacity and Permeability (BCOP) test method was later approved for labeling of products as non-irritants and gained much popularity within numerous industry sectors. Some products however, when formulated purposely to be extremely mild, require a higher resolution of the testing methods to sense subtle changes in composition. Th is challenge prompted industry (manufacturers, testing labs and others in joint eff orts) to design and use other test systems, albeit simpler, but more targeted and sensitive to ingredients and fi nished products with low toxicity profi les. Th us, the maximum simplicity of the in vitro test systems was reached with the monoculture (2D) systems. Continuing the reductionist concept example ( Fig. 1) , Statens Seruminstitut Rabbit Cornea (SIRC) cells have been used to identify minimal to moderate eye irritation potential of chemicals with a good predictive capacity (7) .
It is to be pointed out that all in vitro methods discussed thus far use cell lineages of various animal species origins. Even though standard 2D systems are commonly used in current in vitro toxicology testing strategies because they allow for acquiring large data sets upon exposure to a broad variety of toxicants, their utility is cut short by extrapolation concerns regarding their ability to reliably replicate the responses of their in vivo counterparts (8) . Furthermore, the lack of physiological cell-cell and cellmatrix interactions represents another shortcoming and accounts for the need to add exogenous metabolic activation often times not representative of natural in vivo environment. Due to the inherent limitations of the cell-based assays (and particularly when using lineages of animal origin), three dimensional (3D) reconstructed tissue models based on human cells gained a lot of support in the 2000s. Th ey demonstrate acceptable replication of the in vivo structural and physiological characteristics, including cell viability, proliferation, diff erentiation, morphology, gene and protein expression battery, as well as metabolic function. As outlined in Fig. 1 , human corneal epithelial cells (MatTek Corporation, Ashland, MA, USA) can be used for screening studies due to their unique human features that make them a relevant testing platform compared to similar lineages from animal sources. Th is type of cells are also used to derive reconstructed corneal models such as the EpiCorneal™ (MatTek Corporation) (Fig. 1 ) that can be used to assess the irritation potential of ingredients and fi nal formulations ranging from chemicals to drugs or cosmetics. Th e generation and validation of 3D models for regulatory purposes represents a huge advancement in itself because of increased similarity to native human counterparts and the accommodation of materials that otherwise could not be tested in cell-based assays due to solubility limitations and concerns. However, similar to 2D systems, the methods based on 3D tissue models generally accommodate short substance exposure times (few hours to a few days). While some tissue models can be adapted for repeated exposure regimens (e.g., screening of modulators of skin pigmentation using the tissue models incorporating melanocytes), studies on the mode of action (MoA) at the organ level, and adverse outcome pathways (AOPs) (9) at the systemic organism level, cannot be implemented unless another level of complexity is to be reached by the in vitro lab tools.
Th e next generation of predictive toxicology platforms is represented by bio-printed tissues, and microphysiological systems ("organ on-a-chip"/"body on-a-chip") (reviewed in 10, 11). Th ese platforms have the capability to incorporate the missing features of the 2D cultures (cell-cell interactions, three-dimensional architecture, etc.) and are anticipated to provide increased physiological relevance for molecular, mechanistic, and high-throughput toxicology studies prior to clinical testing. Pharmaceutical industry is once more expected to greatly benefi t from these
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Novel tools in modern toxicology research emerging technologies and to reach maximum capacity and effi cacy when screening libraries of compounds to obtain mechanistic insights from their crosstalk. While the minimum number of organs on a chip is yet to be defi ned by the scientifi c and regulatory community, a goal of ten organs was set by the Defense Advanced Research Projects Agency (DARPA)/National Institutes of Health (NIH) Microphysiological Systems (MPS) program (12) to determine the technical challenges arising from such complex combinations (10) . While commended for their advanced technological design and functionality, the organ/body on-a-chip platforms face several challenges that manufacturers are working assiduously to overcome. For example, they are yet to provide unlimited organoid homeostasis and currently lack physiological regenerative capabilities of cellular repair in the absence of adult stem cells and progenitor niches for local regeneration which are critical for long-term exposure testing. Despite the inherent challenges embedded in all new and yet to be optimized technologies, the recent developments on organ/body on-a-chip models increase the chances for obtaining the long sought ultimate systemic responses based on in vitro systems. Further optimization of these emerging technologies will make them a realistic alternative to systemic acute toxicity testing in animals.
INTEGRATION OF ADVANCED TESTING METHODS INTO PREDICTIVE FRAMEWORKS
With all tools discussed thus far at disposal and potential for new ones, predictive toxicology had the basis to create ingenious frameworks to reach virtually accurate evaluation of hazards and risks without the need for animal-based methods. Th e in vitro/ex vivo methods generally focus on individual key cellular and molecular events to increase the mechanistic understanding of upstream changes. When these events along with the assays capable to investigate them are integrated into an AOP, the overall understanding of how a pathway is aff ected by a toxicant increases signifi cantly.
One of the endpoints assessed as part of the safety evaluation of potential toxicants is skin sensitization that is induced when susceptible individuals are exposed to an allergen and could subsequently develop allergic contact dermatitis upon additional exposure(s). Th e current legislation mandates that investigation of skin sensitization potential and potency of toxicants be assessed using alternative methods to classic animal-based systems (12) . Extensive knowledge of the cellular and molecular components and factors of the skin sensitization pathway has prompted the development of in silico, in chemico and in vitro methods addressing specifi c key events (KEs) and pioneered the development of the AOP for this particular endpoint (Fig. 2a) . Th e AOP for skin sensitization identifi es four KEs: 1) the covalent binding to skin proteins (haptenation) of the parent toxicant/ its derivatives following abiotic/metabolic activation (postulated to be the molecular initiating event); 2) activation of epidermal keratinocytes; 3) activation (maturation) and mobilization of Langerhans cells and dermal dendritic cells (DC); and 4) DC-mediated antigen presentation to naïve T-cells and proliferation/activation of allergen specifi c T-cells. Th e clinical presentation is an infl ammatory response (e.g., erythema, edema, blisters, itching) that occurs in the skin upon re-challenge with an allergen (elicitation phase, Fig. 2a) .
At the beginning of the decision process based on the AOP for skin sensitization are various computational approaches [e.g., Organisation for Economic Co-operation and Development (OECD) Quantitative Structure-Activity Relationship (QSAR) Tool box] that have now reached a stage of maturity and acceptance that allows their participation in the screening cascade to detect sensitizers. Th eir performance is directly related to the accuracy of the data imported and upon which the algorithm is constructed. Th e ideal computational model should be capable to correctly identify true negatives with few false positives (high specifi city) as well as the true positives with few false negatives (high sensitivity). One shortcoming of these models is the incomplete understanding of the eff ect chemical substitutions may have on the toxicants' reactivity and/or their susceptibility for metabolic activation. One immediate use of the computational models is in the initial screening designed to eliminate toxicants with obvious sensitization potential before further investigation. Th is approach aims to minimize false positives and accept false negatives (toxicants that may be later predicted positive when subsequent, more sophisticated and sensitive testing occurs). Th e end goal of this strategy is to detect skin sensitizers before human subjects are exposed to them.
Th e KE#1 (covalent binding to proteins) can be addressed by the Direct Peptide Reactivity Test (DPRA) (14) which is an in chemico method that measures the depletion of synthetic heptapeptides containing either cysteine or lysine following the incubation with the toxicant. Depletion of the peptide in the reaction mixture is measured by High Performance Liquid Chromatography (HPLC) using ultraviolet (UV) detection and separates sensitizers and non-sensitizers based on the level of reactivity with the peptides. Th e KE#2 of the skin sensitization AOP is addressed by the KeratinoSens™ (15), a luciferase reporter gene assay which quantifi es the luciferase gene as an indicator of the activity of the Nrf2 transcription factor in keratinocytes following exposure to the toxicant. Finally, the human cell line activation test (h-CLAT) addresses KE#3 of the skin sensitization AOP by quantifying changes in the expression of cell surface markers associated with the process of activation of monocytes and DC (i.e., CD86 and CD54) in the human monocytic leukaemia cell line THP-1 following exposure to the toxicant (16) . Beyond these cellular events, the organ and organism responses (including sensitization potency) are addressed using in vivo or clinical studies (Fig. 2a) .
Given the complexity of the skin sensitization pathway and the multitude of cellular and molecular events involved, it is unlikely that a single in vitro method is able to accurately assess this critical safety endpoint. Complex analysis of datasets generated in multiple in vitro assays addressing skin sensitization achieved a higher accuracy in predicting a human response when combined (17, 18) . Th e AOP for skin sensitization off ers the perfect example of how Integrated Testing Strategies (ITS) work in presenting a structured, prescriptive, rule-based conceptual framework allowing for the cumulative synthesis of information and maximization of its analysis (Fig. 2b) (19) .
CONCLUSIONS
Th e cross-disciplinary nature of toxicology provided the scaff old for novel, state-of-the art technologies to converge and methodically generate and integrate multiple datasets into frameworks used to ultimately predict human responses to toxicants and to support regulatory and labeling decisions. Initiatives from the U.S. Environmental Protection Agency (EPA) (ToxCast program) or National Research Council (NRC) (Toxicity Testing in the 21st Century: A Vision and a Strategy) (20) guided the direction of toxicity testing away from animal models and towards a wide range of alternative tools discussed herein. Th is cohesive movement came to meet the need to evaluate the safety of a continuously increasing number of ingredients and mixtures and led to an unavoidable paradigm shift in toxicology testing that soon became a widely accepted vision by leading scientifi c and regulatory groups for future toxicology testing. Th e overarching goal of predictive toxicology is to rely on high-throughput, specifi c, sensitive, validated, reliable, reproducible, relevant, easy to perform, transferable, aff ordable, fast alternative methods to animal-based test systems for the prioritization of compounds for further investigations, identifi cation of MoAs and ultimately the development of prediction models for adverse health eff ects in humans.
Taking into consideration the complexity of human responses to the toxicants, it is anticipated that combinatorial analysis of multiple datasets generated in a battery of in vitro, in silico, in chemico, ex vivo, etc. methods is needed to inform a regulatory decision. Th e integration of alternative methods in the AOPs, ITS and IATAs represents a practical refl ection of contemporary concepts in toxicology converging towards reliable frameworks for the prediction of human responses to toxicants. Th e various computational approaches, high-throughput screening assays and increasingly complex model systems described herein are now capable to provide a comprehensive and clinically relevant toxicological profi le and will continue to be refi ned, improved and advanced to ensure safety of products for human use.
